GLP-1 and Creatine: The Science Behind the Supplement Stack That Could Protect Your Muscle

When semaglutide and tirzepatide started delivering 15% or greater reductions in body weight in clinical trials, the medical community celebrated. But inside those impressive numbers was a problem that’s only now getting serious scientific attention: a meaningful portion of that lost weight isn’t fat — it’s muscle. And for men already fighting the slow, metabolically costly battle of preserving lean mass, that’s a tradeoff worth scrutinizing closely. Enter creatine monohydrate — one of the most studied, safest, and least expensive supplements on the market — which researchers are now formally proposing as a frontline tool for protecting muscle during GLP-1-based weight loss.

This isn’t a story only for men on Ozempic or Wegovy. Whether you’re using a GLP-1 receptor agonist, dieting aggressively, deep into a fat-loss phase, or simply trying to hold onto muscle as you age, the underlying biology here applies to you. Rapid caloric restriction, reduced mechanical loading, and lower protein intake are the enemies of skeletal muscle in any context — and creatine has a compelling, mechanistic argument for fighting back against all three.

The Muscle Loss Problem No One Is Talking About Enough

GLP-1 receptor agonists work partly by suppressing appetite — sometimes dramatically. That’s the mechanism that drives weight loss, but it also drives something less desirable: a significant reduction in total food intake that makes it genuinely difficult to hit adequate protein targets. A 2025 narrative review published in Obesity Pillars by Johnson, Milstead, Kreider and colleagues laid out this problem clearly, recommending that GLP-1 users aim for 1.2 to 2.0 grams of protein per kilogram of body weight per day — a target that becomes nearly impossible to hit when appetite is pharmacologically suppressed and total caloric intake is dramatically reduced.

The situation is made worse by what researchers call anabolic resistance. A 2024 retrospective analysis published in Nutrients by Nilsson, Xhuti, de Maat and colleagues found that obesity and metabolic syndrome were among the strongest negative predictors of lean mass gains in response to resistance exercise and protein supplementation. In other words, the men who need muscle preservation the most — those carrying excess body fat and metabolic dysfunction — are also the least responsive to the traditional interventions designed to protect it. That’s a sobering finding, and it raises the stakes considerably for finding adjunct strategies that actually work in this population.

Sarcopenic obesity — the co-existence of excess fat and insufficient muscle — isn’t a minor concern. A 2023 systematic review in Biomedicines by Mellen, Girotto, Marques and colleagues documented the downstream consequences: increased fall risk, cardiovascular and respiratory complications, cognitive decline, and higher rates of hospitalization. Protecting skeletal muscle isn’t vanity — it’s a long-term investment in functional independence and metabolic resilience.

Why Creatine Makes Biological Sense Right Now

A 2026 paper published in Clinical Nutrition by Ostojic, Galyean and colleagues made the formal scientific case for creatine supplementation during GLP-1-based pharmacological weight loss. The argument is elegant and mechanistically grounded. When a man loses weight rapidly — especially under conditions of significant caloric restriction and reduced physical activity — his skeletal muscles face what the researchers call “bioenergetic vulnerability.” The phosphocreatine system is one of the primary energy buffers in muscle tissue, and when intake of dietary creatine (found mostly in red meat and fish) drops alongside overall food intake, intramuscular creatine stores can fall. That’s a problem because those stores are what allow muscles to rapidly regenerate ATP during high-intensity efforts — and without that buffer, muscle function and training capacity both suffer.

The Ostojic paper is careful to note that no randomized clinical trial has directly evaluated creatine supplementation during GLP-1-based weight loss — this is hypothesis-generating science, not a proven protocol. But the biological plausibility is strong, and the safety profile of creatine monohydrate is well-established after decades of research. The authors propose creatine as part of a multimodal muscle-preservation strategy, ideally paired with resistance training and adequate protein intake. That framing is important: creatine isn’t a standalone solution. It’s an amplifier — one that helps the other inputs work better.

The broader evidence base for creatine in sarcopenia prevention is also encouraging. The Biomedicines systematic review cited above specifically identified creatine, leucine, branched-chain amino acids, omega-3s, and vitamin D as supplements with demonstrated benefits for skeletal muscle maintenance. Creatine’s inclusion in that list is meaningful — it’s being evaluated in the same clinical context as nutritional cornerstones of muscle biology. And the Obesity Pillars review by Johnson and Kreider explicitly recommended creatine monohydrate supplementation alongside resistance training for GLP-1 users, placing it alongside whey protein and HMB (beta-hydroxy beta-methylbutyrate) as evidence-based tools for lean mass preservation during weight loss.

For men who aren’t using GLP-1 medications, the calculus is essentially the same during any aggressive fat-loss phase. Caloric deficits reduce dietary creatine intake. Lower food volume makes protein targets harder to hit. Training intensity often suffers when you’re eating less. Creatine addresses all three of these converging pressures by maintaining intramuscular phosphocreatine availability, supporting training performance, and potentially enhancing the anabolic signaling response to resistance exercise. The standard evidence-based dose — 3 to 5 grams of creatine monohydrate daily — is low-cost, well-tolerated, and requires no loading phase to be effective over time.

One additional note on the research landscape: a 2026 trial published in Diabetologia examining a gut-derived peptide called RORDEP1 specifically excluded participants currently using creatine as a dietary supplement during the study period. While this exclusion was procedural — designed to control for confounding variables — it implicitly acknowledges that creatine has meaningful enough physiological effects to alter metabolic outcomes, including those related to GLP-1 signaling. That’s not a direct clinical finding about creatine, but it reflects how seriously researchers are taking its metabolic influence.

What This Means For You

If you’re using a GLP-1 receptor agonist, the muscle-preservation playbook is becoming clearer: prioritize protein aggressively (even if you have to supplement with whey to hit your targets when appetite is suppressed), resistance train consistently, and add creatine monohydrate at 3 to 5 grams per day. The evidence supporting this stack is the strongest it’s ever been, and the cost of not acting — accelerated muscle loss, worsened metabolic health, long-term functional decline — is real.

If you’re not on a GLP-1 medication but you’re in a fat-loss phase, the same logic applies. Creatine is not a supplement for bulk-phase gym bros alone. It’s a biologically rational tool for any man who is eating less, training hard, and trying to protect the muscle he’s built. The research is there. The mechanism is clear. The only question is whether you’re using it.